Search Results - "Desar, I.M.E."

Systemic treatment in adult uterine sarcomas by Desar, I.M.E., Ottevanger, P.B., Benson, C., van der Graaf, W.T.A.

“…Uterine sarcomas (US) are rare mesenchymal tumours of the uterus and are divided mainly into uterine leiomyosarcoma (uLMS), low grade endometrial stromal…”
Get full text

Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy by Desar, I.M.E, van Herpen, C.M.L, van Laarhoven, H.W.M, Barentsz, J.O, Oyen, W.J.G, van der Graaf, W.T.A

“…Summary The development of targeted therapies is a major breakthrough in the treatment of cancer. By evoking necrosis and cavitation, evaluation based on…”
Get full text

A new, simple and objective prognostic score for phase I cancer patients by Füssenich, L.M, Desar, I.M.E, Peters, M.E.W.J, Teerenstra, S, van der Graaf, W.T.A, Timmer-Bonte, J.N.H, van Herpen, C.M.L

“…Abstract Aim To ensure safety and optimise efficacy, careful patient selection for participation in oncologic phase I trials is warranted. Therefore, we did a…”
Get full text

Reply letter to: Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participant – Reply to Füssenich et al.: A new, simple and objective prognostic score for phase I cancer patients by van Herpen, C.M.L, Teerenstra, S, Desar, I.M.E, van der Graaf, W.T.A

Get full text

Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study by Desar, I M E, ter Voert, E G W, Hambrock, Th, van Asten, J J A, van Spronsen, D J, Mulders, P F A, Heerschap, A, van der Graaf, W T A, van Laarhoven, H W M, van Herpen, C M L

“…To assess the early vascular effects of sunitinib in patients with renal cell carcinoma (RCC) with diffusion-weighted magnetic resonance imaging (DWI), dynamic…”
Get full text

P109 Participation and outcome of older adults in phase I trials: a single institution experience by Timmer-Bonte, J.N.H, Füssenich, L, Desar, I.M.E, Kremer, I, van der Graaf, W.T.A, van Herpen, C.M.L

Get full text

1233 A phase I dose escalation study with sorafenib (Sor) in combination with sirolimus (Sir) in patients (pts) with solid tumors by van Herpen, C, Desar, I.M.E, Verijdt, R, van der Graaf, W.T.A, Timmer-Bonte, J.N.H

Get full text

1541P Real-world data from patients with gastrointestinal stromal tumors (GIST) treated in Dutch GIST expertise centers by IJzerman, N.S., Mohammadi, M., Den Hollander, D., Desar, I.M.E., Grünhagen, D.J., Reyners, A.K.L., Mathijssen, R.H., Gelderblom, H., Steeghs, N.

Get full text

537P-SC Exposure-response analysis of cabozantinib in patients with metastatic renal cell cancer treated in routine care by Krens, S.D., van Erp, N.P., Groenland, S., Moes, D.J.A., Desar, I.M.E., Mulder, S.F., Van Der Hulle, T., Steeghs, N., Van Herpen, C.M.

Get full text

1081 The effect of sorafenib on Indium-111 labeled bevacizumab uptake in patients with clear cell renal cell carcinoma (ccRCC) by Desar, I.M.E, Stillebroer, A.B, Oosterwijk, E, Leenders, W.P.J, van Herpen, C.M.L, van der Graaf, W.T.A, Boerman, O.C, Oyen, W.J.G, Mulders, P.F.A

Get full text

Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study by Groenland, S.L., van Eerden, R.A.G., Westerdijk, K., Meertens, M., Koolen, S.L.W., Moes, D.J.A.R., de Vries, N., Rosing, H., Otten, H., Vulink, A.J.E., Desar, I.M.E., Imholz, A.L.T., Gelderblom, H., van Erp, N.P., Beijnen, J.H., Mathijssen, R.H.J., Huitema, A.D.R., Steeghs, N.

“…Oral targeted therapies show a high pharmacokinetic (PK) interpatient variability. Even though exposure has been positively correlated with efficacy for many…”
Get full text

1636PD - Analysis of 105,000 cancer patients: Have they been discussed in oncologic multidisciplinary team meetings? A nationwide population-based study in the Netherlands by Walraven, J.E.W., Desar, I.M.E., Hoeven van der, K.J.J.M, Aben, K.K.H., Van Hillegersberg, R., Rasch, C.R.N., Lemmens, V.E.P.P, Verhoeven, R.H.A.

“…For optimal oncological care it is recommended to discuss every patient with cancer in a multidisciplinary team meeting (MDTM). Due to increasing incidence and…”
Get full text

Analysis of 105,000 cancer patients: Have they been discussed in oncologic multidisciplinary team meetings? A nationwide population-based study in the Netherlands by Walraven, J.E.W., Desar, I.M.E., Hoeven van der, K.J.J.M, Aben, K.K.H., Van Hillegersberg, R., Rasch, C.R.N., Lemmens, V.E.P.P, Verhoeven, R.H.A.

Get full text

1626MO Treatment expectations and preferences for quality versus quantity of life in patients with advanced soft tissue sarcomas starting palliative 1st line chemotherapy by Younger, E., Jones, R.L., Den Hollander, D., Soomers, V., Desar, I.M.E., Young, R., Oosten, A., Gelderblom, H., De Haan, J.J., Steeghs, N., Husson, O., Van Der Graaf, W.T.A.

Get full text

731P The impact of proton pump inhibitors on pazopanib exposure by Krens, S.D., Lubberman, F., Van Egmond, M., Jansman, F., Burger, D., Hamberg, P., Vervenne, W., Gelderblom, H., Desar, I.M.E., Van Herpen, C., Van Erp, N.

Get full text

601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours by Gelderblom, H., Gietema, J.A., Desar, I.M.E., Ajmone, N.M., Jalving, M., Kroep, J.R., Nicolas, V., Vaslin, A., Tobal, K., Purcea, D., van Haren, S.F., Damstrup, L.

Get full text

2041TiP - Health-related quality of life in patients with advanced soft tissue sarcomas treated with chemotherapy: The HOLISTIC study by Younger, E., Husson, O., Desar, I.M.E., Young, R., Leahy, M.G., Oosten, A., Gelderblom, H., de Haan, J., Steeghs, N., Jones, R.L., van der Graaf, W.T.

“…Around half of patients with intermediate or high-grade soft tissue sarcomas (STS) will develop advanced disease. The mainstay of treatment for advanced STS is…”
Get full text

1680P - A global patient-driven Facebook study in a very rare sarcoma: Health-related quality of life in epithelioid hemangioendothelioma (EHE) patients by Weidema, M.E., Husson, O., van der Graaf, W.T., Leonard, H., de Rooij, B.H., De Young, L Hartle, Desar, I.M.E., van de Poll-Franse, L.V.

“…EHE is a vascular sarcoma with an incidence of≤1 per 1 million/year, and an unpredictable clinical course with significant symptom burden. Recruiting EHE…”
Get full text

1705P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) by Ijzerman, N.S., Drabbe, C., Den Hollander, D., Mohammadi, M., van Boven, H., Desar, I.M.E., Gelderblom, H., Grünhagen, D.J., Reyners, A.K.L., Mathijssen, R.H.J., Steeghs, N., van der Graaf, W.T.A.

“…GIST in older adults and in children are well-known entities, but this is not the case for AYA patients with GIST. Typically, GIST in children (70% female)…”
Get full text

Health-related quality of life in patients with advanced soft tissue sarcomas treated with chemotherapy: The HOLISTIC study by Younger, E., Husson, O., Desar, I.M.E., Young, R., Leahy, M.G., Oosten, A., Gelderblom, H., de Haan, J., Steeghs, N., Jones, R.L., van der Graaf, W.T.

Get full text